medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Number 3

<< Back Next >>

Ann Hepatol 2017; 16 (3)

The Prevalence of Parkinson Disease Among Patients With Hepatitis C Infection

Golabi, Pegah; Otgonsuren, Munkhzul; Sayiner, Mehmet; Arsalla, Aimal; Gogoll T, Younossi ZM

Language: English
References: 32
Page: 342-348
PDF size: 145.93 Kb.


ABSTRACT

Introduction. HCV has been suspected to potentially cause degenerations in the central nervous system. Parkinson's disease is the second most common neurodegenerative disorder. Our aim was to assess the prevalence of Parkinson's disease among patients with HCV infection. Material and methods. For this study, we used Medicare database from 2005-2010. Medicare database contains information on enrollment, coverage, diagnosis recorded with International Classification of Disease, Ninth Revision (ICD- 9). From combined inpatient and outpatient files, Parkinson's disease was identified as the first diagnosis by ICD-9 code 332.0. Other study variables were; age, gender, race (White and No White), and Medicare eligibility status. Simple distribution comparison by HCV status examined with t-test for numerical variables and χ2 test for categorical variables in the main analytical cohort as well as in the propensity score matched cohort. Results. A total of 1,236,734 patients (median age 76 years, 41% male, and 85% White) was identified among over 47 million claims. Of these, 6040 patients (0.5%) were infected with HCV. Overall, 0.8% (N = 49) of the HCV group and 1.3% (N = 16,004) of the Non-HCV group had Parkinson's disease (P ‹ 0.001). When the study groups matched for age, gender and race, the prevalence of Parkinson's disease was similar between HCV and Non-HCV groups (P › 0.05). Discussion. This study revealed that, among Medicare population, HCV was not associated with Parkinson disease.


REFERENCES

  1. Fazel Y, Lam B, Golabi P, Younossi Z. Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf 2015; 14: 1317-26.

  2. Younossi ZM, LaLuna LL, Santoro JJ, Mendes F, Araya V, Ravendhran N, Pedicone L, et al. Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot study. BMC Gastroenterol 2016; 16: 45.

  3. Younossi ZM, Otgonsuren M, Henry L, Arsalla Z, Stepnaova M, Mishra A, Venkatesan C, et al. Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States. J Viral Hepat 2015; 22: 137-45.

  4. Golabi P, Otgonsuren M, Suen W, Koenig AB, Noor B, Younossi ZM. Predictors of Inpatient Mortality and Resource Utilization for the Elderly Patients With Chronic Hepatitis C (CH-C) in the United States. Medicine (Baltimore) 2016; 95: e2482.

  5. Sayiner M, Wymer M, Golabi P, Ford J, Srishord I, Younossi ZM. Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation. Aliment Pharmacol Ther 2016; 43: 1060-8.

  6. Afendy A, Kallman JB, Stepanova M, Younoszai Z, Aquino RD, Bianchi G, Marchesini G, et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 2009; 30: 469-76.

  7. Kallman J, O'Neil MM, Larive B, Boparai N, Calabrese L, Younossi ZM. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 2007; 52: 2531-9.

  8. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 2016; 3: 3-14.

  9. Rosenthal E, Cacoub P. Extrahepatic manifestations in chronic hepatitis C virus carriers. Lupus 2015; 24: 469-82.

  10. Wu WY, Kang KH, Chen SL, Chiu SY, Yen AM, Fann JC, Su CW, et al. Hepatitis C virus infection: a risk factor for Parkinson's disease. J Viral Hepat 2015; 22: 784-91.

  11. Tsai HH, Liou HH, Muo CH, Lee CZ, Yen RF, Kao CH. Hepatitis C virus infection as a risk factor for Parkinson disease: A nationwide cohort study. Neurology 2016; 86: 840-6.

  12. Schapira AH. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol 2013; 26: 395-400.

  13. Jang H, Boltz DA, Webster RG, Smeyne RJ. Viral parkinsonism. Biochim Biophys Acta 2009; 1792: 714-21.

  14. Adinolfi LE, Nevola R, Lus G, Restivo L, Guerrera B, Romano C, Zampino R, et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol 2015; 21: 2269-80.

  15. Fletcher NF, McKeating JA. Hepatitis C virus and the brain. J Viral Hepat 2012; 19: 301-6.

  16. Rifai MA, Indest D, Loftis J, Hauser P. Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol 2006; 9: 508-19.

  17. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kent Kwoh C. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepat 2007; 14: 890-6.

  18. Liu Z, Zhao F, He JJ. Hepatitis C virus (HCV) interaction with astrocytes: nonproductive infection and induction of IL-18. J Neurovirol 2014; 20: 278-93.

  19. Golden J, O'Dwyer AM, Conroy RM. Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors. Gen Hosp Psychiatry 2005; 27: 431-8.

  20. Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. HCV-related nervous system disorders. Clin Dev Immunol 2012; 2012: 236148

  21. Monaco S, Mariotto S, Ferrari S, Calabrese M, Zanusso G, Gajofatto A, Sansonno D, et al. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. World J Gastroenterol 2015; 21: 11974-83.

  22. Stasi C, Zignego AL, Laffi G, Rosselli M. The liver-cytokinebrain circuit in interferon-based treatment of patients with chronic viral hepatitis. J Viral Hepat 2011; 18: 525-32.

  23. Lee MH, Yang HI, Jen CL, Lu SN, Yeh SH, Liu CJ, You SL, et al. Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991-2. Gut 2011; 60: 688-94.

  24. Bennett H, Waser N, Johnston K, Kao JH, Lim YS, Duan ZP, Lee YJ, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int 2015; 9: 378-90.

  25. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011; 53: 737-45.

  26. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, Luma HN, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol 2014; 60: 691-8.

  27. Smith BD, Beckett GA, Yartel A, Holtzman D, Patel N, Ward JW. Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999- 2008. Am J Public Health 2014; 104: 474-81.

  28. Deming P, Martin MT, Chan J, Dilworth TJ, El-Lababidi R, Love BL, Mohammad RA, et al. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2016; 36: 203-17.

  29. Kao JH. Hepatitis C virus infection in Taiwan: Past, present, and future. J Formos Med Assoc 2016; 115: 65-6.

  30. Montenegro L, De Michina A, Misciagna G, Guerra V, Di Leo A. Virus C hepatitis and type 2 diabetes: a cohort study in southern Italy. Am J Gastroenterol 2013; 108: 1108-111.

  31. Garcia-Compean D, Gonzalez-Gonzalez JA, Lavalle-Gonzalez FJ, Gonzalez-Moreno EI, Villarreal-Perez JZ, Maldonado- Garza HJ. Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy. Dig Dis Sci 2016; 61: 371-80.

  32. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.




2020     |     www.medigraphic.com